Sponsors in 2008

ERBI's BioPartnering Exchange could not take place without its sponsors - their support helps drive the service we provide through the event and we extend our thanks to them.

Merck Sharp & Dohme

The UK subsidiary of Merck & Co., Inc., Whitehouse Station, NJ, USA, is a global research-driven pharmaceutical company dedicated to putting patients first. Merck discovers, develops, manufactures, and markets vaccines and medicines in over 20 therapeutic categories directly and through its joint ventures. Our mission is to provide society with superior products and services by developing innovations and solutions that improve the quality of life. At Merck, our strategy for growth is based on breakthrough research — both internal and external through partnerships — and demonstrating the value of our medicines to patients, payers, and providers. Worldwide sales in 2006 were $22.6 billion and Merck continues to invest heavily in research and development. Merck's product line includes a broad portfolio of highly innovative prescription products in important therapeutic areas. Human health products include medicines to treat high blood pressure, elevated cholesterol levels, diabetes, cancer, osteoporosis, asthma, benign prostatic hypertrophy, arthritis, pain, migraine, glaucoma, infectious diseases (antibiotic, antifungal, and antiviral agents), and vaccines (to prevent childhood diseases, human papilloma virus, shingles, and hepatitis A and hepatitis B).

For information visit www.msd-uk.com

Abingworth Management Ltd

Abingworth was founded in 1973 and is a key player among life science venture capital investors with offices in London, Cambridge (UK), Menlo Park, California and Boston, Massachusetts.

Specialising in life science and biomedical companies, Abingworth now has funds under management of over $1.25 billion and 25 staff including experienced professionals with operational, venture capital and public market investment expertise.

The company has backed more than 100 life science/medical firms, most of which have gone public or been acquired. Abingworth is a strongly science driven investment organisation that is prepared to take on substantial technical risk.

The management team has many years of operating experience and can actively assist scientific entrepreneurs in the development of their ideas into successful companies. Abingworth has the experience and resources to assist companies at any stage of development and take them beyond the IPO stage..

Website: www.abingworth.com
Email: info@abingworth.com

London Technology Network

LTN (London Technology Network) is a not-for-profit, government-funded initiative that enables technology intensive companies worldwide to engage effectively with the region's universities, including Imperial College London, UCL, UEA, Cambridge, Cranfield, Surrey and Oxford universities. LTN's technology consultants are experienced industry practitioners specialising in life sciences, high technology and engineering, who assist higher education institutes to turn their 'ideas into action'.

LTN’s technology consultants refine the need of a company regarding innovation into either an offer of technology or a request for collaboration. This is then sent out to LTN’s network of academic and industry contacts. Successful matches are made possible because LTN’s scope is vast, with contacts in 35+ universities across the Greater South-East. LTN also hold regular networking events on topics covering all industry sectors: life sciences, ICT, process and product industries.

Since 2004 LTN has also hosted the London office of the Innovation Relay Centre Network, a European-wide network of 220 business development offices in 33 countries.

To find out more visit www.ltnetwork.org, www.london-irc.org, or call 0870 765 7602.

BTG

BTG in-licenses, develops and commercialises pharmaceuticals principally in the areas of neuroscience and oncology. The company has a substantial and growing revenue stream of royalties from out-licensed products and a broad, expanding internal pipeline of development programmes.

Our Focus

BTG is interested in acquiring clinical stage products that have completed Phase I studies and are ready for further clinical development. We have expertise in developing novel NCE programmes, as well as repositioned compounds. We will review and determine the best development strategy for each asset on a project by project basis, undertaking the development alone or in collaboration if we believe that would enhance the product’s value. Our areas of focus include Pain Therapeutics, Symptomatic Treatments for Neurodegenerative Disorders, Sleep Disorders and Oncology Supportive Care.

BTG operates from offices in London, Philadelphia and Osaka. For more information see www.btgplc.com

RSA

RSA is a leading global provider of executive search, recruitment, interim management and consulting services to the Life Science and Healthcare Sectors.

Established for 25 years RSA has built up an unparalleled network of industry contacts and a reputation for delivering quality services

We deliver solutions to Clients across the world from six wholly-owned offices in USA, Europe and Asia.

Visit our website at www.theRSAgroup.com to find out more.

UKTI

UK Trade & Investment is the government organisation that exists to help ambitious companies seek out new markets and seize new opportunities.  We intend to help businesses everywhere extend their horizons.

The work of UK Trade & Investment includes:

1. Trade support services for UK companies, provided nationally through a network of over 40 offices.
2. Inward investment development work within the UK, in collaboration with UK regional development agencies.
3. The trade and investment work of British embassies, high commissions and consulate generals worldwide.
4. National co-ordination of trade development across other government departments, devolved administrations and the English regions.

For more information about the work of UK Trade & Investment please visit www.uktradeinvest.gov.uk

EEI

East of England International provides business support to companies seeking to trade internationally and assists foreign-owned businesses looking to invest in the region.

Our International Trade Advisers deliver UK Trade & Investment programmes to local businesses while our Business Development Managers provide free and confidential advice to overseas companies, saving clients valuable management time and costs. Our service includes arranging site visits, supplying local and regional socio-economic data, advice on recruitment, introductions to university research contacts and industry partners, and providing supply chain information. Our Investor Development programme provides on-going support to companies located in the East of England.

 

Hewitsons

Businesses flourish because of their ability to adapt and we're no exception. With the Cambridge area home to the largest cluster of bioscience activity outside North America, we've developed a highly regarded specialist team to advise clients both locally and further afield. As one of the largest law firms in our region, our work also covers all aspects of corporate, commercial and property law, as well as addressing the legal needs of charities, institutions and private individuals. Our clients are as diverse as the work we do. But in whatever we do for you, we personalise our services to suit your needs.
We have offices in Cambridge, Milton Keynes, Northampton and Saffron Walden and our size, resources and sheer range of specialist expertise
means that whatever your legal needs we will look after you.

To find out more visit: www.hewitsons.com

Reddie & Grose

 

To find out more visit: www.reddie.co.uk

Chesterford Research Park

Chesterford Research Park offers state-of-the-art laboratory and office space, specifically designed for research, establishing itself and the wider South Cambridge area, as one of the UK’s leading R&D locations.

Our Focus

Chesterford Research Park provides the very best working environment for people and businesses from the BioTech and R&D sector. Not only is it an established development, it is also a growing community.

It is evolving into a unique scientific centre for the UK, with sensitive expansion plans and a firm vision for the future.

Now in its eighth year, the vision for Chesterford Research Park is to create state-of-the-art laboratory and office space, specifically designed for research and biotech companies. Since its inception in 2000, joint developers of Chesterford Research Park, The Churchmanor Estates Company plc and Morley Fund Management have created more than 250,000 sq ft (23,225 sq m) of accommodation and put in place the infrastructure, facilities, and management systems to be able to bring forward some 600,000 sq ft (over 55,740 sq m) of development.

The proposed development programme at the Park aims to provide high quality, flexible accommodation for companies at all stages of their life cycle, with the team working closely with its occupiers, to continually satisfy their property requirements, as they change and grow.

For more information visit www.chesterfordresearchpark.co.uk

 

 

"We are delighted to support a regional event which is definitely more international as each year goes by." Tim Sparey, Merck Sharpe & Dohme